Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)

NCT03776487 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03776487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03776487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 7, 2019
Completion date
December 30, 2026
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage 0 gastric cancer ajcc v8, clinical stage 0 gastroesophageal junction adenocarcinoma ajcc v8, clinical stage i gastric cancer ajcc v8, clinical stage i gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iib gastric cancer ajcc v8, clinical stage iib gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, gastric adenocarcinoma, localized gastric carcinoma, localized gastroesophageal junction adenocarcinoma, pathologic stage 0 gastric cancer ajcc v8, pathologic stage 0 gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage i gastric cancer ajcc v8, pathologic stage ia gastric cancer ajcc v8, pathologic stage ia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ib gastric cancer ajcc v8, pathologic stage ib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ic gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iia gastric cancer ajcc v8, pathologic stage iia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iib gastric cancer ajcc v8, pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia gastric cancer ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8